Becton, Dickinson and Company

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

Vicarious Surgical is a next-generation robotics company developing a disruptive technology with the goal of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. Vicarious Surgical aims to revolutionize the field of minimally invasive surgery by developing advanced robotic systems that allow surgeons to perform complex procedures with greater precision and control. The company's robotic system is designed to be compact and portable, enabling it to be easily integrated into existing operating rooms without significant modifications. The robot's design also aims to minimize the invasiveness of surgical procedures, leading to faster patient recovery times and reduced post-operative discomfort.

HealthNet provides high-quality medical, dental, behavioral health care and support services to people of all age, regardless of insurance.

Tepha is a medical device firm pursuing the development and commercialization of innovative products based on the company's proprietary biomaterial technology. The technology provides a new class of absorbable biomaterials, known as polyhydroxyalkanoates , which may be tailored to meet unmet needs for medical devices in multiple fields. Tepha's novel, biosynthetically produced materials offer superior performance in flexibility, elasticity, and biocompatibility; and, for its fiber-based products, excellent tensile strength and strength retention.

Velano Vascular is a medical device innovator committed to reducing the pain, risk and inefficiencies of traditional blood collection practices while enhancing the clinical domain of vascular access. The company’s revolutionary FDA-approved PIVO device expands the use of peripheral IV lines for frequent, high quality blood draws, aiming to deliver painless, compassionate care for hospital inpatients, a safer practice for caregivers, and a more financially responsible alternative for health systems. More information is available at www.velanovascular.com.

GSL Solutions is a medical technology company that develops devices for storing and tracking controlled substances. They also provide patient-specific medications that improve the security, efficiency, and compliance of medication storage.

Cubex Systems is the developer of cloud-based inventory management software. The company's inventory management software offers real-time reporting to deliver intuitive analytics that prioritizes operational demands, spend management and regulatory compliance, enabling the medical, dental and veterinary markets to lower costs associated with medication and optimize inventory supply management.

TVA Medical, Inc. (TVA) is a medical device company developing innovative, minimally invasive therapies for treatment of End-Stage Renal Disease (ESRD). The company is funded by Santé Ventures.

MedAware provides innovative solutions that save lives, improve patient safety, and significantly reduce healthcare costs. MedAware’s patent-pending technology uses big data analytics and machine learning algorithms to analyze large scale data of electronic medical records, and learn automatically how physicians treat patients in real life scenarios. With MedAware, healthcare providers, payers, and pharmacy chains can leverage their big data to identify and eliminate a wide range of prescription errors and provide better risk management. Founded in 2012, MedAware is based in Raanana, Israel.

Magentiq Eye Ltd. was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growing power of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective- ultimately saving millions of lives and billions of dollars. Our first product is APDS: Automatic Polyp Detection System, developed to be used in online and offline colonoscopies. Our APDS (Automatic Polyp Detection System) can point out the suspicious locations of polyps in the videos, increasing the attentiveness of doctors during procedures, thus helping them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The APDS- RT runs on the video feed from the endoscopic camera used by the physician in real time during the endoscopic procedure (currently only on Colonoscopy Procedure). The APDS-OFL is a software that runs in off-line mode on pre-Recorded Colonoscopy Videos. It is estimated that 40 million colonoscopy procedures are performed every year (almost 40% in the US alone). The ability of colonoscopy procedures to decrease the number of colon cancer cases has been proven without a doubt and their number expected to grow. However, researches have shown that there is about 25% of misses (undetected polyps) in those procedures, misses which can, unfortunately, cause interval cancer. Within this context The APDS can be sold as an add-on to the colonoscopy system or as a service (license per exam), paid by the clinic or hospital. Once the APDS system would be formally proven, during the next year, to improve polyp detection rate, it could be sold either jointly with the endoscopic equipment providers or it can be integrated in the colonoscopy devices.

C. R. Bard, headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

Caesarea Medical Electronics Ltd. designs and develops a range of infusion and syringe pumps in the United States. It offers epidural infusion, dual and four channel infusion, ambulatory syringe, and enteral feeding and syringe pumps, as well as intravenous medication delivery and multi functional infusion therapy devices, and a range of disposable administration sets. The company also provides accessories, including chargers, carrying pouches, carrying back bags, syringe pump carrying pouch waist or shoulders straps, lock boxes, and cables. Its products are used by clinical research companies; and various treatment settings, such as hospital, homecare, and transport or emergency medicine. The company was founded in 1993 and is based in Caesarea, Israel.

CRISI Medical Systems, Inc. (CRISI) is a privately-funded medical device company dedicated to improving the safety and delivery of intravenous (IV) injectable medications through technology and innovation. They are on the forefront of companies developing developing innovative solutions to advance the standard of care in injectable drug delivery.

GenCell Biosystems is developing revolutionary technologies for molecular biology. GenCell Biosystems is commercializing a number of instruments based upon their innovative Composite Liquid Cell platform technology. Composite Liquid Cells (CLCs) provide an entirely new method of confining, transporting, combining, processing and analysing biological reactions to yield valuable data. With applications including sample extraction and preparation, library preparation for next-gen sequencing, PCR genotyping, qPCR, digital PCR and proteomic assays, CLCs are versatile and can be tailored to suit virtually all protocol requirements.

CareFusion provides medical products and enterprise management solutions. Their medical technology products include automated dispensing, patient identification systems, respiratory ventilators, and surgical instruments required for infection prevention, neurological monitoring, and diagnosis. They help healthcare organizations achieve infection control, medication management, medical supply management, and respiratory care improvements.

Alverix focuses on producing low cost, handheld reader devices with the accuracy and precision of laboratory instrumentation. The company partners with diagnostic and OEM manufacturers seeking to increase current test accuracy, improve the portability of existing tests, or develop new assays for use in physician offices, laboratory outreach locations, retail clinics, and patient homes. With strength in product design, product development, and high volume manufacturing, Alverix is leading the transition of diagnostic testing from the laboratory to all locations where immediate results are critical to patient care.

Cato Software Solutions provides an automated system that creates and shares data to help reduce human error, standardize practice.

Safety Syringes, Inc. designs, manufactures, and markets safety devices for the pharmaceutical industry in the United States, Canada, Europe, India, and the Russian Federation. It offers UltraSafe needle guards to attach to prefilled glass syringes used with vaccines, low molecular weight heparins, and other medicines.

Harnessing the power of novel light-harvesting polymeric materials, Sirigen’s amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. Sirigen’s versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications.

BD Kiestra Total Lab Automation develops solutions and services for medical bacteriology laboratories. It offers total lab and work cell automation solutions, and automation/mechanization modules. The company also provides solutions and products for use in a water or food microbiology laboratories.

Carmel Pharma ab engages in the manufacture and distribution of products that improve the quality of life of people who prepare, administer, and dispose of hazardous drugs. It offers the PhaSeal System, a closed-system drug transfer device that prevents hazardous drug interaction with the environment. The company's PhaSeal product is implemented in various cancer centers, oncology practices, and specialty pharmacies in the United States, as well as facilities in Europe and Asia. Carmel Pharma ab was founded in 1994 and is headquartered in Mölndal, Sweden with an additional office in Columbus, Ohio.

Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

CYTOPEIA INC serves the Manufacturing - Test & Measurement industry from their SEATTLE, WA office

Plasso Technology is develops surface-critical research tools utilizing functional coating technology for applications in glycomics and cell culture. The company offers BD Heparin Binding Plate that immobilizes the heparin without modification

TriPath Imaging, Inc. manufactures and markets diagnostic equipment and products for cervical cytology screening. The company’s products include microbial identification tests for differential detection and identification of the causative agents for vaginitis; ethanol based fixative systems to collect, preserve, hemolyze, transport, and transfer cytology specimens to a glass slide; slide profilers for prioritizing slides based on likelihood of abnormality to help cytotechnologists reduce false negatives;

GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.

Atto Bioscience, established in 1985, specializes in providing innovative solutions for pharmaceutical, academic, and research sectors focused on cellular biology. The company offers a unique integration of biology, imaging instrumentation, engineering, and manufacturing, resulting in a comprehensive suite of assays, instrumentation, and services tailored for the life sciences and toxicology communities. With a strong emphasis on in-house technology development, Atto Bioscience adapts quickly to customer needs, delivering state-of-the-art imaging solutions for drug discovery and cellular research. Since reorganizing in 2001, Atto has expanded its capabilities by recruiting leading scientists and enhancing its management team, which has facilitated its entry into the high-throughput cell imaging market. The company's technologies support various applications, from secondary screening techniques to pre-clinical research, promoting efficient strategies that reduce time and increase success rates in drug development.

StemCo Biomedical, Inc. was founded in 1999 and is located in the Research Triangle Park area of NC. The Company is engaged in the development, manufacture and distribution of a series of medical products designed to improve therapeutic transplantation of adult hematopoetic stem and progenitor cells derived from bone marrow, peripheral blood or umbilical cord blood. Addressing a market of more than $1 billion annually, the Company will have a series of products on the market starting in 2002 that identify, sort and custom-engineer stem cell grafts based upon cellular expression of ALDH resulting in what may be better, more effective stem cell transplants in the future.

GENTEST Corporation is dedicated to the development of novel systems for the in vitro analysis of xenobiotic (drug) metabolism and toxicity. GENTEST scientists are internationally recognized as leaders and innovators in cytochrome P450 cDNA-expression and in vitro xenobiotic techniques. Their demonstrated commitment to research has been rewarded by the receipt of several competitive NIH grants. The results and applications of Their research is reported in peer reviewed journals and at international symposia by both GENTEST scientists and Their colleagues/customers in xenobiotic metabolism. GENTEST began operations in 1983, initially focusing on the use of cultured human cells in GLP genotoxicity assays. In 1985, They expanded research activities into the area of xenobiotic metabolism by developing cytochrome P450 cDNA-expression approaches. This led to the first commercial offering of cDNA-expressed human cytochrome P450 enzymes in 1990. Since that time the range of GENTEST products, human cytochrome P450 forms and other xenobiotic-metabolizing enzymes, as well as the specific activity of enzymes in Their products, has increased dramatically.

Saf-T-Med, Inc. (STM), a Chicago-based developer of patented needle technology designed to protect health care workers against accidental needlestick injuries.

Clontech Laboratories provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, Clontech is part of a company that holds a leadership position in the global market and is committed to improving the human condition through biotechnology. Clontech's mission is to develop high-quality innovative tools and services to accelerate discovery.

As of February 9, 1999, Biometric Imaging, Inc. was acquired by Becton, Dickinson and Company. Biometric Imaging, Inc. develops cell based diagnostic products and high throughput drug discovery technology. Their research is based on a proprietary technology called microvolume fluorimetry, and they primarily serve the transfusion medicine, infectious diseases, and oncology markets. The company was founded in 1991 and is based in Mountain View, California.